Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders

Drug Development Research

Volumn 67, Issue 9, 2006, Pages 757-769

  Witkin, Jeffrey M ^a   Eiler II, William J A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cognition; Depression; Forced swim test; LY341495; MGlu2 3 receptors; MGS0039; Schizophrenia

Indexed keywords

2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DESIPRAMINE; DIAZEPAM; DONEPEZIL; EGLUMETAD; FLUVOXAMINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; IMIPRAMINE; LY 314582; LY 366457; LY 392098; LY 487379; METABOTROPIC RECEPTOR 2; QUINPIROLE; RIMONABANT;

AGONIST; ANXIETY DISORDER; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; EPILEPSY; MENTAL DISEASE; MOOD DISORDER; NEUROLOGIC DISEASE; NONHUMAN; PAIN; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; STROKE;

EID: 33845575789     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20144     Document Type: Review

References (91)

1. Adewale AS, Platt DM, Spealman RD. 2006. Pharmacological stimulation of Group II metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys. J Pharmacol Exp Ther. May 4 [Epub ahead of print].
2. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. 2006. A role for AMPA receptors in mood disorders. Biochem Pharmacol 71:1273-1288.
3. Arcella A, Carpinelli G, Battaglia G, D'Onofrio M, Santoro F, Ngomba RT, Bruno V, Casolini P, Giangaspero F, Nicoletti F. 2005. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neurooncol 7:236-245.
4. Barker GR, Bashir ZI, Brown MW, Warburton EC. 2006. A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. Learn Mem 13:178-186.
5. Bond A, Jones NM, Hicks CA, Whiffin GM, Ward MA, O'Neill MF, Kingston AE, Monn JA, Ornstein PL, Schoepp DD, Lodge D, O'Neill MJ. 2000. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J Pharmacol Exp Ther 294:800-809.
6. Borsini F, Podhorna J, Marazziti D. 2002. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163:121-141.
7. Cartmell J, Schoepp DD. 2000. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907.
8. Cartmell J, Monn JA, Schoepp DD. 2000. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400:221-224.
9. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. 2001. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40:847-855.
10. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A. 2004. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457-467.
11. Conn PJ, Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
12. Cortese BM, Phan KL. 2005. The role of glutamate in anxiety and related disorders. CNS Spectr 10:820-830.
13. Cryan JF, Markou A, Lucki I. 2002. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238-245.
14. Cryan JF, Hoyer D, Markou A. 2003. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54:49-58.
15. David HN, Abraini JH. 2001. Differential modulation of the D1-like- and D2-like dopamine receptor-induced locomotor responses by group II metabotropic glutamate receptors in the rat nucleus accumbens. Neuropharmacology 41:454-463.
16. Duman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606.
17. Feinberg I, Campbell IG, Schoepp DD, Anderson K. 2002. The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacol Biochem Behav 73:467-474.
18. Feinberg I, Schoepp DD, Hsieh KC, Darchia N, Campbell IG. 2005. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4, 6-dicarboxylate] in rats. J Pharmacol Exp Ther 312:826-833.
19. Folbergrova J, Druga R, Otahal J, Haugvicova R, Mares P, Kubova H. 2005. Seizures induced in immature rats by homocysteic acid and the associated brain damage are prevented by group II metabotropic glutamate receptor agonist (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate. Exp Neurol 192:420-436.
20. Galici R, Echemendia NG, Rodriguez AL, Conn PJ. 2005. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181-1187.
21. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ. 2006. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318:173-185.
22. Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ. 2002. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav 73:317-326.
23. Gleason SD, Shannon HE. 1997. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84.
24. Grassi S, Frondaroli A, Pettorossi VE. 2005. Role of group II metabotropic glutamate receptors 2/3 and group I metabotropic glutamate receptor 5 in developing rat medial vestibular nuclei. Neuroreport 16:1303-1307.
25. Gregory ML, Stech NE, Owens RW, Kalivas PW. 2003. Prefrontal group II metabotropic glutamate receptor activation decreases performance on a working memory task. Ann N Y Acad Sci 1003:405-409.
26. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, Woltering T, Nakanishi S, Mutel V. 2004. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46:907-917.
27. Iversen L. 2005. The monoamine hypothesis of depression. In: Licinio J, Wong ML, editors. Biology of depression. Weinheim: Wiley-VCH. p 71-86.
28. Johnson MP, Chamberlain M. 2002. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 43:799-808.
29. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD. 2003. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy) phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3- ylmethylamine. J Med Chem 46:3189-3192.
30. Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HE. 2005. Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models alter acute and repeated dosing. Neuropharmacology 49(suppl 1):206-218.
31. Karasawa J, Shimazaki T, Kawashima N, Chaki S. 2005. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 1042:92-98.
32. Karasawa J, Yoshimizu T, Chaki S. 2006. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett 393:127-130.
33. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A. 2005. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 378:131-134.
34. Kenny PJ, Markou A. 2004. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 25:265-272.
35. Kenny PJ, Gasparini F, Markou A. 2003. Group II metabotropic and AMPA/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306:1068-1076.
36. Kew JN, Kemp JA. 2005. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179:4-29.
37. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD. 1998. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37:1-12.
38. Kingston AE, O'Neill MJ, Lam A, Bales KR, Monn JA, Schoepp DD. 1999. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol 377:155-165.
39. Knapp RJ, Goldenberg R, Shock C, Cecil A, Watkins J, Miller C, et al. 2002. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 440:27-35.
40. Lee Y, Duman RS, Marek GJ. 2006. The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression. Neurosci Lett 398:328-332.
41. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. 2001. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40:1028-1033.
42. Li X, Witkin JM, Need AB, Skolnick P. 2003. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003;23:419-430.
43. Li X, Morrow D, Witkin JM. 2006. Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 78:1933-1939.
44. Linden AM, Bergeron M, Schoepp DD. 2005. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo. Neuropharmacology 49(suppl 1):120-134.
45. Linden AM, Greene SJ, Bergeron M, Schoepp DD. 2004. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 29:502-513.
46. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ. 2003. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28:1622-1632.
47. Losonczy A, Somogyi P, Nusser Z. 2003. Reduction of excitatory postsynaptic responses by persistently active metabotropic glutamate receptors in the hippocampus. J Neurophysiol 89:1910-1919.
48. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. 2000. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76-87.
49. Marino MJ, Conn PJ. 2006. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 6:98-102.
50. Markou A, Kosten TR, Koob GF. 1998. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135-174.
51. Matarredona ER, Santiago M, Venero JL, Cano J, Machado A. 2001. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 76:351-360.
52. Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM. 2001. Glutamate-hypothalamic-pituitary-adrenal qaxis interactions: implications for mood and anxiety disorders. CNS Spectr 6:555-556, 561-564.
53. Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricasole A, Scaccianoce S, Riozzi B, Melchiorri D, Nicoletti F. 2002. Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 42:1008-1015.
54. Matrisciano F, Scaccianoce S, Del Bianco P, Panaccione I, Canudas AM, Battaglia G, Riozzi B, Ngomba RT, Molinaro G, Tatarelli R, Melchiorri D, Nicoletti F. 2005. Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J Neurochem 93:1345-1352.
55. Mela F, Marti M, Fiorentini C, Missale C, Morari M. 2006. Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine. Mol Cell Neurosci 31:284-292.
56. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. 2005. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 25:6389-6393.
57. Nakamura M, Kawakita Y, Yasuhara A, Fukasawa Y, Yoshida K, Sakagami K, Nakazato A. 2006. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino- 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid), a potent metabotropic glutamate receptor antagonist. Drug Metab Dispos 34:369-374.
58. Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, Nakamura M, Chaki S. 2004. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem 47:4570-4587.
59. Neto FL, Castro-Lopes JM. 2000. Antinociceptive effect of a group II metabotropic glutamate receptor antagonist in the thalamus of monoarthritic rats. Neurosci Lett 296:25-28.
60. Ngomba RT, Biagioni F, Casciato S, Willems-van Bree E, Battaglia G, Bruno V, Nicoletti F, van Luijtelaar EL. 2005. The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spike-wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology. 49(suppl 1):89-103.
61. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH. 2004. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89:876-885.
62. O'Neill MF, Heron-Maxwell C, Conway MW, Monn JA, Ornstein P. 2003. Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 45:565-574.
63. Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD. 1998. 2-Substituted (2SR)-2-amino-2-((1SR, 2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterisation, and bioavailability. J Med Chem 41:358-378.
64. Pilc A, Legutko B. 1995. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. Neuroreport 7:85-88.
65. Poli A, Beraudi A, Villani L, Storto M, Battaglia G, Di Giorgi Gerevini V, Cappuccio I, Caricasole A, D'Onofrio M, Nicoletti F, 2003. Group II metabotropic glutamate receptors regulate the vulnerability to hypoxic brain damage. J Neurosci 23:6023-6029.
66. Rasmussen K, Hsu MA, Vandergriff J. 2004. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons. Neuropharmacology 46:620-628.
67. Rorick-Kelm LM, Hart JC, McKinzie DL. 2005. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl) 183:226-240.
68. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809.
69. Sato T, Tanaka K, Ohnishi Y, Irifune M, Nishikawa T. 2003. Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice. Neural Plast 10:319-325.
70. Sato T, Ishida T, Tanaka K, Ohnishi Y, Irifune M, Mimura T, Nishikawa T. 2005. Ameliorative and exacerbating effects of [pGlu(4),Cyt(6)]AVP((4-9)) on impairment of step-through passive avoidance task performance by group II metabotropic glutamate receptor-related drugs in mice. J Pharmacol Sci 97:437-442.
71. Scaccianoce S, Matrisciano F, Del Bianco P, Caricasole A, Di Giorgi Gerevini V, Cappuccio I, Melchiorri D, Battaglia G, Nicoletti F. 2003. Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis. Neuropharmacology 44:555-561.
72. Schoepp DD. 2001. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12-20.
73. Schoepp DD, Conn PJ. 1993. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13-20.
74. Schoepp DD, Marek GJ. 2002. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1:215-225.
75. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. 2003. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189-197.
76. Shimazaki T, Iijima M, Chaki S. 2004. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 501:121-125.
77. Simmons RM, Webster AA, Kalra AB, Iyengar S. 2002. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 73:419-427.
78. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. 2002. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 99:3182-3187.
79. Swanson CJ, Schoepp DD. 2003. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann N Y Acad Sci 1003:309-317.
80. Vogel GW. 1983. Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 16(suppl 1):103S-108S.
81. Wang JQ, Arora A, Yang L, Parelkar NK, Zhang G, Lin X, Choe ES, Mao L. 2005. Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol Neurobiol 32:237-249.
82. Winter JC, Eckler JR, Rabin RA. 2004. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl) 172:233-240.
83. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. 2005. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 26:609-617.
84. Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. 2001. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 298:453-460.
85. Wroblewska B, Wegorzewska IN, Bzdega T, Olszewski RT, Neale JH. 2006. Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. J Neurochem 96:1071-1077.
86. Wu J, Rowan MJ, Anwyl R. 2004. An NMDAR-independent LTP mediated by group II metabotropic glutamate receptors and p42/44 MAP kinase in the dentate gyrus in vitro. Neuropharmacology 46:311-317.
87. Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, Ohta H, Nakazato A. 2006. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6- fluorobicyclo[3.].0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg Med Chem 14:4193-4207.
88. Yoon MH, Choi J, Bae HB, Kim SJ, Chung ST, Jeong SW, Chung SS, Yoo KY, Jeong CY. 2006. Antinociceptive effects and synergistic interaction with morphine of intrathecal metabotropic glutamate receptor 2/3 antagonist in the formalin test of rats. Neurosci Lett 394:222-226.
89. Yoshimizu T, Chaki S. 2004. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 315:493-496.
90. Yoshimizu T, Shimazaki T, Ito A, Chaki S. 2006. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186:587-593.
91. Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK. 2003. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28:45-52.